SuperworthProtagonist Therapeutics EPS PTGX
Diluted earnings per share by quarter and over the last twelve months, from 2015.
- Last 12 months, to Jun 30, 2026
- $1.03
- Latest quarter, Q2 FY26
- $2.29
- Fiscal year 2025
- −$2.05
- −149% on the year before
Protagonist Therapeutics' earnings per share was $1.03 over the twelve months to Jun 30, 2026, up 47% on a year earlier.
In its latest quarter, Q2 FY26, it was $2.29.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$2.05 | −149% |
| FY2024 | $4.20 | n/a |
| FY2023 | −$1.48 | n/a |
| FY2022 | −$2.60 | n/a |
| FY2021 | −$2.70 | n/a |
| FY2020 | −$2.00 | n/a |
| FY2019 | −$3.00 | n/a |
| FY2018 | −$1.72 | n/a |
| FY2017 | −$2.17 | n/a |
| FY2016 | −$61.57 | n/a |
| FY2015 | −$58.75 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $2.29 | n/a | $1.03 | |
| Q1 FY26 | $0.05 | n/a | −$1.81 | |
| Q4 FY25 | −$0.69 | −135% | −$2.05 | |
| Q3 FY25 | −$0.62 | n/a | $0.62 | |
| Q2 FY25 | −$0.55 | n/a | $0.70 | |
| Q1 FY25 | −$0.19 | −106% | $0.75 | |
| Q4 FY24 | $1.98 | +340% | $4.20 | |
| Q3 FY24 | −$0.54 | n/a | $2.67 | |
| Q2 FY24 | −$0.50 | n/a | $2.63 | |
| Q1 FY24 | $3.26 | n/a | $2.45 | |
| Q4 FY23 | $0.45 | n/a | −$1.48 | |
| Q3 FY23 | −$0.58 | n/a | −$2.62 |
Against its peers
Companies in Drug Manufacturers - General nearest Protagonist Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| PTGXProtagonist Therapeutics | $1.03 | +47% a year |
| CORTCorcept Therapeutics | $0.42 | −63% a year |
| TGTXTG Therapeutics | $2.74 | +641% a year |
| BMRNBiomarin Pharmaceutical | $0.37 | −89% a year |
| ALKSAlkermes plc. | $0.38 | −82% a year |
| AMRXAmneal Pharmaceuticals | $0.49 | +4800% a year |
| LGNDLigand Pharmaceuticals | $9.40 | |
| KNSAKiniksa Pharmaceuticals International | $0.97 | +2325% a year |
| JAZZJazz Pharmaceuticals | $14.62 | |
| INDVIndivior Pharmaceuticals | $2.78 | +227% a year |
| ARQTArcutis Biotherapeutics | $0.22 | |
| Peer median | $0.73 |
Where Protagonist Therapeutics ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Protagonist Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.